Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity

Authors:

Abstract
No abstract available
Funding Information
  • Boehringer Ingelheim
  • Ministry of Education, Culture, Sports, Science and Technology

This publication has 10 references indexed in Scilit: